Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,162,691
  • Shares Outstanding, K 118,014
  • Annual Sales, $ 7,530 K
  • Annual Income, $ -526,240 K
  • EBIT $ -525 M
  • EBITDA $ -513 M
  • 60-Month Beta 0.78
  • Price/Sales 815.28
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 55.16% ( -6.12%)
  • Historical Volatility 45.84%
  • IV Percentile 18%
  • IV Rank 8.28%
  • IV High 291.99% on 12/19/23
  • IV Low 33.79% on 06/03/24
  • Put/Call Vol Ratio 0.41
  • Today's Volume 1,973
  • Volume Avg (30-Day) 2,224
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 83,657
  • Open Int (30-Day) 90,271

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.24
  • Number of Estimates 10
  • High Estimate -0.59
  • Low Estimate -1.60
  • Prior Year -1.38
  • Growth Rate Est. (year over year) +10.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.41 +10.15%
on 11/22/24
59.39 -12.07%
on 11/11/24
+0.90 (+1.75%)
since 10/25/24
3-Month
47.41 +10.15%
on 11/22/24
59.39 -12.07%
on 11/11/24
-3.63 (-6.50%)
since 08/27/24
52-Week
30.68 +70.21%
on 11/28/23
110.25 -52.63%
on 01/08/24
+20.39 (+64.06%)
since 11/27/23

Most Recent Stories

More News
Insider Sale: EVP Research & Development of $CYTK (CYTK) Sells 2,000 Shares

Fady Ibraham Malik, the EVP Research & Development of $CYTK ($CYTK), sold 2,000 shares of the company on 11-26-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

CYTK : 52.22 (+0.38%)
Insider Sale: Director at $CYTK (CYTK) Sells 742 Shares

WENDALL WIERENGA, a director at $CYTK ($CYTK), sold 742 shares of the company on 11-25-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.9% of their shares....

CYTK : 52.22 (+0.38%)
Cytokinetics and Bayer Announce €70 Million Collaboration for Aficamten Development in Japan to Treat Hypertrophic Cardiomyopathy

Cytokinetics and Bayer partner to develop aficamten for hypertrophic cardiomyopathy in Japan, involving substantial payments and milestone incentives.Quiver AI SummaryCytokinetics and Bayer have announced...

CYTK : 52.22 (+0.38%)
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

CYTK : 52.22 (+0.38%)
Cytokinetics Presents New Data on Omecamtiv Mecarbil from GALACTIC-HF Trial at AHA Scientific Sessions 2024

Cytokinetics presented new analyses on omecamtiv mecarbil's efficacy in heart failure at the AHA Scientific Sessions 2024.Quiver AI SummaryCytokinetics, Incorporated announced new findings from post-hoc...

CYTK : 52.22 (+0.38%)
Cytokinetics Presents Promising New Data on Aficamten for Hypertrophic Cardiomyopathy at AHA Scientific Sessions 2024

New analyses show Aficamten improves oxygen uptake recovery, quality of life, and reduces septal reduction therapy eligibility in HCM patients.Quiver AI SummaryCytokinetics, Incorporated announced new...

CYTK : 52.22 (+0.38%)
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

CYTK : 52.22 (+0.38%)
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024

CYTK : 52.22 (+0.38%)
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference

CYTK : 52.22 (+0.38%)
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

CYTK : 52.22 (+0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 54.00
2nd Resistance Point 53.42
1st Resistance Point 52.82
Last Price 52.22
1st Support Level 51.64
2nd Support Level 51.06
3rd Support Level 50.46

See More

52-Week High 110.25
Fibonacci 61.8% 79.85
Fibonacci 50% 70.46
Fibonacci 38.2% 61.08
Last Price 52.22
52-Week Low 30.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar